Nelson Sonja 4
4 · Ambrx Biopharma Inc. · Filed Jan 31, 2023
Insider Transaction Report
Form 4
Nelson Sonja
Chief Fin. & Operating Officer
Transactions
- Award
Employee Stock Option (right to buy)
2023-01-27+2,574,596→ 2,574,596 totalExercise: $0.28Exp: 2031-09-01→ Ordinary Shares (2,574,596 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2023-01-27−850,000→ 0 totalExercise: $0.64Exp: 2032-02-22→ Ordinary Shares (850,000 underlying) - Award
Employee Stock Option (right to buy)
2023-01-27+850,000→ 850,000 totalExercise: $0.28Exp: 2032-02-22→ Ordinary Shares (850,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2023-01-27−425,000→ 0 totalExercise: $0.64From: 2023-02-23Exp: 2032-02-22→ Ordinary Shares (425,000 underlying) - Award
Employee Stock Option (right to buy)
2023-01-27+425,000→ 425,000 totalExercise: $0.28From: 2023-02-23Exp: 2032-02-22→ Ordinary Shares (425,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2023-01-27−2,574,596→ 0 totalExercise: $2.56Exp: 2031-09-01→ Ordinary Shares (2,574,596 underlying)
Footnotes (4)
- [F1]Twenty-five percent of the Ordinary Shares subject to the option vested on June 30, 2022, and the remainder vests in thirty-six equal monthly installments following such date.
- [F2]The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents seven Ordinary Shares of the Issuer.
- [F3]The option held by the reporting person was amended to reduce the exercise price.
- [F4]Twenty-five percent of the Ordinary Shares subject to the option vests on February 23, 2023, and the remainder vests in thirty-six equal monthly installments following such date.